Skip to content

STUDY TO ASSESS THE EFFECTIVENESS OF VIRECHANA, NISHAKATAKADI KASHAYAM & GUDUCHI CHURNA TABLET IN THE MENEGMENT OF JATOTTAR-PRAMEHA (DIABETES MELLITUS TYPE-2)

EVALUATION OF EFFICACY OF TREATMENT REGIMEN CONSISTING OF VIRECHANA, NISHAKATAKADI KASHAYAM & GUDUCHI CHURNA TABLET IN THE MANAGEMENT OF JATOTTAR-PRAMEHA (DIABETES MELLITUS TYPE-2) - A RANDOMIZED CONTROLLED TRIAL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/10/046227
Enrollment
1050
Registered
2022-10-06
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

Ministry of AYUSH Government of India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Individuals between the age of 16 to 70 years of either sex without any discrimination of cast and religion. 2. Individuals suitable for Shodhana (Virechana) Procedure. 3. Individuals with blood sugar fasting 126mg/dl to 200mg/dl and (or) post prandial plasma glucose level 200mg/dl to 275mg/dl 4. Probably all such cases would be newly diagnoses cases of diabetes. 5. Those who will sign the written informed consent.

Exclusion criteria

Exclusion criteria: 1. Known case of Insulin Depended Diabetes Mellitus (IDDM). 2. Individuals suffering from diseases like cancer, tuberculosis, sever cardiovascular diseases are other systemic diseases. 3. Individuals suffering from other endocrinopathies like acromegaly, Cushingââ?¬•s syndrome. 4. Individuals with genetic syndromes like Downââ?¬•s syndrome, Klinefelterââ?¬•s syndrome, Turnerââ?¬•s syndrome. 5. Pregnant and lactating women. 6. Any other condition which can jeopardise the outcome of the study will be excluded.

Design outcomes

Primary

MeasureTime frame
Improvement in hematological and laboratory parameters (FBS, PPBS, HbA1c).Timepoint: 3 months

Secondary

MeasureTime frame
Safety effects of drugs on liver and renal functions (LFT, RFT)Timepoint: 3 months

Countries

India

Contacts

Public ContactDr Nitin Ujjaliya

Pt. Khushilal Sharma Government Ayurveda College and Institute Bhopal

umeshayurvedabhopal@gmail.com9425373046

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026